M. A. Bakhtadze
Research Subjects
M. A. Bakhtadze has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail L. Kukushkin
Research Institute of General Pathology and Pathophysiology
11 shared publications - Maxim V. Churyukanov
Sechenov First Moscow State Medical University (Sechenov University)
10 shared publications - O. S. Davydov
Research Institute of General Pathology and Pathophysiology
10 shared publications - Aleksei I. Isaikin
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
6 shared publications - P. P. Kalinsky
Pacific State Medical University
6 shared publications - Aleksandr E. Barulin
Volgograd State Medical University
5 shared publications
Latest Publications
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”
In June 2025, an Expert Council of the Russian Association for the Study of Pain (RASP) was held. Specialists discussed the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of nonspecific (musculoskeletal) lower back pain. The meeting presented data from studies of efficacy and safety of aceclofenac, ketoprofen, lornoxicam, nimesulide, pelubiprofen, tenoxicam in the treatment of musculoskeletal back pain.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”
In June 2025, an Expert Council of the Russian Association for the Study of Pain (RASP) was held. Specialists discussed the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of nonspecific (musculoskeletal) lower back pain. The meeting presented data from studies of efficacy and safety of aceclofenac, ketoprofen, lornoxicam, nimesulide, pelubiprofen, tenoxicam in the treatment of musculoskeletal back pain.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Clinical efficacy and safety of L-lysine aescinate in the complex therapy of painful radiculopathy due to lumbar compression: results of a randomized, double-blind, placebo-controlled study
A randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of L-lysine aescinate as part of the combination therapy for acute lumbar compressive radiculopathy with pain. The study included 246 patients, 123 of whom received the study drug and 123 received placebo. The study showed that the inclusion of a 10-day course of L-lysine aescinate in the standard therapy regimen for acute lumbar compressive radiculopathy provided an additional reduction in pain intensity according to the visual analogue scale by an average of 13.7 mm (lower limit of 95% Confidence Interval (CI) is 11 mm); reliable differences appeared as early as the 5th day of therapy and persisted by the 11th day from the start of treatment. L-lysine aescinate added to the standard therapy regimen provided complete pain relief 11 times more often (27% vs. 2.4% of patients) compared to standard therapy in combination with placebo. The addition of L-lysine aescinate to the standard treatment regimen for radiculopathy provided additional improvement in patients’ daily living parameters. The magnitude of additional improvement on the 11th day from the start of treatment averaged 9.6% (lower limit of 95% CI is 7.4%) according to the Oswestry questionnaire, on average 2.8 points (lower limit of 95% CI is 2.0 points) according to the Roland-Morris questionnaire; reliable differences were noted as early as the 5th day of therapy and were maintained. Furthermore, the inclusion of a 10-day course of L-lysine aescinate in the standard therapy regimen, compared with standard therapy in combination with placebo, resulted in a 2.4-fold decrease (15% vs. 37%) in the proportion of patients experiencing difficulty or requiring assistance in performing daily activities, a 6.8-fold increase (28% vs. 4%) in the proportion of patients who could cope with all daily activities, and a 10.5-fold increase (34% vs. 3%) in the proportion of patients with no impairments in daily activities. The clinical improvements described above were achieved with acceptable safety, represented by an adverse reaction rate of 4.5% and the absence of serious adverse events and drug discontinuations due to intolerance. Thus, the inclusion of L-lysine aescinate in the standard treatment regimen for acute lumbar radiculopathy can increase the effectiveness of treatment and provide additional benefits in the form of a significantly more significant reduction in pain intensity and improvement in the daily functioning of patients with acceptable safety of such treatment.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Clinical efficacy and safety of L-lysine aescinate in the complex therapy of painful radiculopathy due to lumbar compression: results of a randomized, double-blind, placebo-controlled study
A randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of L-lysine aescinate as part of the combination therapy for acute lumbar compressive radiculopathy with pain. The study included 246 patients, 123 of whom received the study drug and 123 received placebo. The study showed that the inclusion of a 10-day course of L-lysine aescinate in the standard therapy regimen for acute lumbar compressive radiculopathy provided an additional reduction in pain intensity according to the visual analogue scale by an average of 13.7 mm (lower limit of 95% Confidence Interval (CI) is 11 mm); reliable differences appeared as early as the 5th day of therapy and persisted by the 11th day from the start of treatment. L-lysine aescinate added to the standard therapy regimen provided complete pain relief 11 times more often (27% vs. 2.4% of patients) compared to standard therapy in combination with placebo. The addition of L-lysine aescinate to the standard treatment regimen for radiculopathy provided additional improvement in patients’ daily living parameters. The magnitude of additional improvement on the 11th day from the start of treatment averaged 9.6% (lower limit of 95% CI is 7.4%) according to the Oswestry questionnaire, on average 2.8 points (lower limit of 95% CI is 2.0 points) according to the Roland-Morris questionnaire; reliable differences were noted as early as the 5th day of therapy and were maintained. Furthermore, the inclusion of a 10-day course of L-lysine aescinate in the standard therapy regimen, compared with standard therapy in combination with placebo, resulted in a 2.4-fold decrease (15% vs. 37%) in the proportion of patients experiencing difficulty or requiring assistance in performing daily activities, a 6.8-fold increase (28% vs. 4%) in the proportion of patients who could cope with all daily activities, and a 10.5-fold increase (34% vs. 3%) in the proportion of patients with no impairments in daily activities. The clinical improvements described above were achieved with acceptable safety, represented by an adverse reaction rate of 4.5% and the absence of serious adverse events and drug discontinuations due to intolerance. Thus, the inclusion of L-lysine aescinate in the standard treatment regimen for acute lumbar radiculopathy can increase the effectiveness of treatment and provide additional benefits in the form of a significantly more significant reduction in pain intensity and improvement in the daily functioning of patients with acceptable safety of such treatment.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Role of disease-modifying drugs in osteoarthritis and pharmaconutraceuticals in the treatment of chronic non-specific back pain
In September 2025, an expert council meeting was held to discuss the role and importance of disease-modifying drugs for osteoarthritis and pharmaconutraceuticals in the treatment of chronic nonspecific back pain. This meeting presented data from studies examining efficacy and safety of bioactive extract and concentrate from small sea fish, chondroitin sulfate, glucosamine and their combinations, as well as some pharmaconutraceuticals in the treatment of musculoskeletal back pain. There is a need to include these agents in clinical guidelines for the management of chronic musculoskeletal back pain for its effective and safe management and prevention.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Role of disease-modifying drugs in osteoarthritis and pharmaconutraceuticals in the treatment of chronic non-specific back pain
In September 2025, an expert council meeting was held to discuss the role and importance of disease-modifying drugs for osteoarthritis and pharmaconutraceuticals in the treatment of chronic nonspecific back pain. This meeting presented data from studies examining efficacy and safety of bioactive extract and concentrate from small sea fish, chondroitin sulfate, glucosamine and their combinations, as well as some pharmaconutraceuticals in the treatment of musculoskeletal back pain. There is a need to include these agents in clinical guidelines for the management of chronic musculoskeletal back pain for its effective and safe management and prevention.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach
Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach
Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.
- 20 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (1) , 22-30
Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis
Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.
- 20 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (1) , 22-30
Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis
Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.
- 22 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (4)
The Neck Disability Index: modification of the “Driving” item of the Russian language version
Objective. 1. To supplement the “Driving” item of the Neck Disability Index (NDI) with information assessing the impact of neck pain on the ability to move around by public and private transport. 2. To evaluate the psychometric properties of the modified version of this questionnaire. Material and methods. The object of the study is a modified (2020) Russian-language version of the NDI. At the first stage, we performed retrospective analysis of filled questionnaires and calculated percentage of omissions for the “Driving” item. At the second stage, the “Driving” item was modified, and psychometric properties of new version were assessed. Study participants were 337 patients (221 women and 116 men) aged 18-65 years with non-specific neck pain, tension type headache, migraine and cervicogenic headache (CeH). Results. A retrospective analysis revealed that the “Driving” item was omitted in 83 (43%) out of 194 questionnaires completed by patients with neck pain. To eliminate omissions, the name of this item was changed to “Using transportation / driving”, and each statement was supplemented with phrase “I use transportation...”, for example: “I use transportation / drive a car without any neck pain at all”. This modification eliminated omissions when filling out the questionnaires. The questionnaire demonstrated good internal consistency: Cronbach’s α=0.89; inter-item correlation coefficient=0.47. Factor analysis revealed a 2-factor structure of the Index. In the 2nd factor, “Headache” (0.878) and “Concentration of attention” (0.876) items had the highest factor loading. Cluster analysis revealed three separate non-overlapping clusters of patients with no, mild, and moderate disability. The group with no disability consisted mainly of patients with non-specific neck pain. The group with moderate disability consisted mainly of patients with chronic migraines, including that combined with chronic CeH. Conclusion. The Russian language version of the Neck Disability Index, modified to assess patients’ ability to use transportation, is a reliable instrument with good psychometric properties, ready for use in everyday practice and clinical trials.
- 22 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (4)
The Neck Disability Index: modification of the “Driving” item of the Russian language version
Objective. 1. To supplement the “Driving” item of the Neck Disability Index (NDI) with information assessing the impact of neck pain on the ability to move around by public and private transport. 2. To evaluate the psychometric properties of the modified version of this questionnaire. Material and methods. The object of the study is a modified (2020) Russian-language version of the NDI. At the first stage, we performed retrospective analysis of filled questionnaires and calculated percentage of omissions for the “Driving” item. At the second stage, the “Driving” item was modified, and psychometric properties of new version were assessed. Study participants were 337 patients (221 women and 116 men) aged 18-65 years with non-specific neck pain, tension type headache, migraine and cervicogenic headache (CeH). Results. A retrospective analysis revealed that the “Driving” item was omitted in 83 (43%) out of 194 questionnaires completed by patients with neck pain. To eliminate omissions, the name of this item was changed to “Using transportation / driving”, and each statement was supplemented with phrase “I use transportation...”, for example: “I use transportation / drive a car without any neck pain at all”. This modification eliminated omissions when filling out the questionnaires. The questionnaire demonstrated good internal consistency: Cronbach’s α=0.89; inter-item correlation coefficient=0.47. Factor analysis revealed a 2-factor structure of the Index. In the 2nd factor, “Headache” (0.878) and “Concentration of attention” (0.876) items had the highest factor loading. Cluster analysis revealed three separate non-overlapping clusters of patients with no, mild, and moderate disability. The group with no disability consisted mainly of patients with non-specific neck pain. The group with moderate disability consisted mainly of patients with chronic migraines, including that combined with chronic CeH. Conclusion. The Russian language version of the Neck Disability Index, modified to assess patients’ ability to use transportation, is a reliable instrument with good psychometric properties, ready for use in everyday practice and clinical trials.
- 10 September 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (3)
The Central Sensitization Inventory: modification for tension-type headache, migraine and cervicogenic headache
Objective. To reduce the CSI to optimal list of statements reflecting symptoms of patients with neck pain, TTH, migraine and CGH. Material and methods. The floor and ceiling effects were assessed in 192 patients with headaches. Factor and cluster analysis of shortened CSI, as well as its internal consistency were assessed in 240 patients suffering from neck pain and headaches. Results. The CSI was shortened to 14-item form. This form has a single-factor structure including 4 domains identifying hypersensitivity; muscle tension and pain; fatigue, tiredness and mental impairment; impairment of emotional functions and low stress resistance. It has good internal consistency (Cronbach’s α = 0.85) and identifies mild (cut-off point ≤24), moderate (cut-off point >24) and severe (cut-off point ≥34) symptoms of central hypersensitivity. Conclusion. The shortened form of the Central Sensitization Inventory can be successfully used in daily practice and clinical trials of patients suffering from neck pain and headache.
- 10 September 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (3)
The Central Sensitization Inventory: modification for tension-type headache, migraine and cervicogenic headache
Objective. To reduce the CSI to optimal list of statements reflecting symptoms of patients with neck pain, TTH, migraine and CGH. Material and methods. The floor and ceiling effects were assessed in 192 patients with headaches. Factor and cluster analysis of shortened CSI, as well as its internal consistency were assessed in 240 patients suffering from neck pain and headaches. Results. The CSI was shortened to 14-item form. This form has a single-factor structure including 4 domains identifying hypersensitivity; muscle tension and pain; fatigue, tiredness and mental impairment; impairment of emotional functions and low stress resistance. It has good internal consistency (Cronbach’s α = 0.85) and identifies mild (cut-off point ≤24), moderate (cut-off point >24) and severe (cut-off point ≥34) symptoms of central hypersensitivity. Conclusion. The shortened form of the Central Sensitization Inventory can be successfully used in daily practice and clinical trials of patients suffering from neck pain and headache.
- Open Access
- 16 December 2024
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16 (6) , 4-10
Central lumbar stenosis. Recommendations of the Russian Association for the Study of Pain (RASP)
Narrowing of the central spinal canal in the lumbar spine (central lumbar stenosis, CLS) is one of the most common causes of lumbar pain, disability and spinal surgery in the elderly. The most common is acquired degenerative CLS, in which the main role play lumen-narrowing medial intervertebral disc herniating with ossification phenomena and marginal bone proliferation on the sides of the vertebral bodies – osteophytes, hypertrophy of the facet joints with their medial displacement, hypertrophy of the yellow ligament. The development of CLS can also be a consequence of spondylolisthesis, postoperative changes, rheumatic diseases and other causes. Both the compression of the cauda equine roots due to narrowing of the spinal canal and their ischemia, caused by compression of the radicular vessels and venous congestion play an important role in the pathogenesis of CLS. CLS develops in elderly age and occurs predominantly in men. The main clinical manifestation of CLS is neurogenic (caudogenic) intermittent claudication, which manifests as pain, numbness and weakness in the legs when the patient walks or stands for a long time but subsides when the patient sits or stands and bends forwards (flexion in the lumbar spine). The diagnosis of CLS is confirmed by magnetic resonance imaging (MRI), which shows a narrowing of the spinal canal and makes it possible to rule out specific causes of lumbar pain. It is important to note that, according to MRI, CLS often occurs at an older age, so its detection in the absence of clinical manifestations does not require an immediate discussion of the prospects of surgical treatment. Pain in patients with CLS according to MRI may be musculoskeletal in nature. Therefore, the diagnosis of CLS should include specific clinical manifestations and stenosis on MRI. In patients without clinical manifestations of CLS, osteoporosis and severe concomitant somatic diseases, only conservative therapy is recommended. Modern conservative treatment of CLS includes an educational program, therapeutic exercises (kinesiotherapy), psychological therapy methods for emotional disorders (cognitive-behavioral therapy), manual therapy and pharmacotherapy. Complex conservative treatment of CLS can reduce pain, improve the patient's condition and in some cases increase the patient's walking distance.
- 16 December 2024
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16 (6) , 4-10
Open AccessCentral lumbar stenosis. Recommendations of the Russian Association for the Study of Pain (RASP)
Narrowing of the central spinal canal in the lumbar spine (central lumbar stenosis, CLS) is one of the most common causes of lumbar pain, disability and spinal surgery in the elderly. The most common is acquired degenerative CLS, in which the main role play lumen-narrowing medial intervertebral disc herniating with ossification phenomena and marginal bone proliferation on the sides of the vertebral bodies – osteophytes, hypertrophy of the facet joints with their medial displacement, hypertrophy of the yellow ligament. The development of CLS can also be a consequence of spondylolisthesis, postoperative changes, rheumatic diseases and other causes. Both the compression of the cauda equine roots due to narrowing of the spinal canal and their ischemia, caused by compression of the radicular vessels and venous congestion play an important role in the pathogenesis of CLS. CLS develops in elderly age and occurs predominantly in men. The main clinical manifestation of CLS is neurogenic (caudogenic) intermittent claudication, which manifests as pain, numbness and weakness in the legs when the patient walks or stands for a long time but subsides when the patient sits or stands and bends forwards (flexion in the lumbar spine). The diagnosis of CLS is confirmed by magnetic resonance imaging (MRI), which shows a narrowing of the spinal canal and makes it possible to rule out specific causes of lumbar pain. It is important to note that, according to MRI, CLS often occurs at an older age, so its detection in the absence of clinical manifestations does not require an immediate discussion of the prospects of surgical treatment. Pain in patients with CLS according to MRI may be musculoskeletal in nature. Therefore, the diagnosis of CLS should include specific clinical manifestations and stenosis on MRI. In patients without clinical manifestations of CLS, osteoporosis and severe concomitant somatic diseases, only conservative therapy is recommended. Modern conservative treatment of CLS includes an educational program, therapeutic exercises (kinesiotherapy), psychological therapy methods for emotional disorders (cognitive-behavioral therapy), manual therapy and pharmacotherapy. Complex conservative treatment of CLS can reduce pain, improve the patient's condition and in some cases increase the patient's walking distance.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (4)
Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution
Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (4)
Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution
Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (4)
The Keele stratification tool for targeted treatment of musculoskeletal pain (Keele STarT MSK Tool): linguistic adaptation of the Russian-language version
Objective. Linguistic adaptation of the Russian-language version of the Keele STarT MSK Tool questionnaire. Material and methods. Linguistic adaptation of the Russian-language version of the Keele STarT MSK Tool questionnaire was carried out in 5 stages, including direct and reverse translations, discussion by experts and testing of patients with musculoskeletal pain. Results. After linguistic adaptation, we obtained the Russian-language version of the Keele STarT MSK Tool questionnaire. This questionnaire is conceptually similar to original version and understandable for doctors and patients. This version consists of 2 separate forms. One of them is intended to be filled in by a clinician, the other one — for self-completion by patients (https://keelelicencing.org/tool-download). Conclusion. The Keele STarT MSK Tool questionnaire allows stratifying patients with musculoskeletal pain into subgroups with low, moderate and high risk of unfavorable course for targeted treatment. The Russian-language version of this questionnaire is adapted and ready for assessing its psychometric properties.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (4)
The Keele stratification tool for targeted treatment of musculoskeletal pain (Keele STarT MSK Tool): linguistic adaptation of the Russian-language version
Objective. Linguistic adaptation of the Russian-language version of the Keele STarT MSK Tool questionnaire. Material and methods. Linguistic adaptation of the Russian-language version of the Keele STarT MSK Tool questionnaire was carried out in 5 stages, including direct and reverse translations, discussion by experts and testing of patients with musculoskeletal pain. Results. After linguistic adaptation, we obtained the Russian-language version of the Keele STarT MSK Tool questionnaire. This questionnaire is conceptually similar to original version and understandable for doctors and patients. This version consists of 2 separate forms. One of them is intended to be filled in by a clinician, the other one — for self-completion by patients (https://keelelicencing.org/tool-download). Conclusion. The Keele STarT MSK Tool questionnaire allows stratifying patients with musculoskeletal pain into subgroups with low, moderate and high risk of unfavorable course for targeted treatment. The Russian-language version of this questionnaire is adapted and ready for assessing its psychometric properties.